Market news

On September 8, Bausch Health Companies Inc. (NYSE:BHC) and Belgian skincare innovator YUN announced they are extending their microbiome-focused dermatology partnership into Mexico and five additional markets spanning Central and Eastern Europe and Central Asia. The move builds on a 2025 launch in Poland and lands just weeks after the company raised its full-year guidance […]

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

Bausch Health (BHC) said Tuesday it expanded its collaboration with biotech firm Yun to expand acces

Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, today announced the availability of Fraxel FTX® in Australia, expanding access to its latest skin resurfacing technology to Australian health care practitioners (HCPs) beginning September 1, 2026.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program. Since launching in 2013, the program has awarded 87 scholarships, totaling over $1 million, to students who have been treated for dermatologic conditions. This year, six inspiring students will each receive up to $10,000 to support their undergraduate or graduate studies.

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2026 Salix Gastrointestinal Health Scholars Program. For the seventh year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education.

Bausch Health Companies Inc. stock jumped 40% after Q2 beats and higher FY2026 guidance, but $15B debt risk persists. Click for more on BHC stock.

Much of this was due to a very well-received quarterly earnings report.

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

VAUGHAN, Ontario, August 06, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors.

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

Bausch Health (NYSE:BHC) climbed by 28.85 percent on Thursday to end at $6.03 apiece, after announcing a strong second quarter of the year that set the ground for the company’s profit recovery. In an updated report, the pharmaceutical giant said that it swung to a net income of $260 million during the period, marking a […]

BHC beats Q2 estimates as Salix, Solta Medical and Bausch + Lomb fuel growth, lifting 2026 revenue and EBITDA guidance after strong earnings.

(Updates with the latest stock movement in the first paragraph and headline.) Bausch Health (BHC)

Bausch Health (BHC) reported Q2 adjusted earnings late Wednesday of $1.26 per diluted share, up from

Moby summary of Bausch Health Companies Inc.'s Q2 2026 earnings call

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch (BHC) delivered earnings and revenue surprises of +31.25% and +7.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2026 financial results and other key updates from the quarter.

Bausch Health Companies (BHC.TO, BHC) rose 4.1% in after-hours trading after reporting adjusted seco

Bausch Health Cos (NYSE:BHC) reported second-quarter results that management said extended its streak of revenue and adjusted EBITDA growth to 13 consecutive quarters, driven by performance in its Salix, international and Solta Medical businesses. For Bausch Health excluding Bausch + Lomb, second-q

Announces that PrELIDEL® (pimecrolimus) cream is now listed under Alberta's public drug plan for eligible ...

Bausch Health Companies Inc. (NYSE:BHC) is one of the 15 best NYSE penny stocks to buy according to hedge funds. On July 6, Bausch Health Companies Inc.’s (NYSE:BHC) subsidiary, Bausch Health Canada, shared the listing of PrOKEDI’s 75mg and 100mg dosages in the Régie de l’assurance maladie du Québec (RAMQ) formulary. PrOKEDI is an injectable […]

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Will release second-quarter 2026 financial results after market close on Wednesday, July 29. Bausch ...

VAUGHAN, Ontario, July 06, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the cal